NanoBio to Present Intranasal Pertussis Vaccine Data

“The resurgence of pertussis infections in the United States and worldwide has become quite concerning, as infections in the U.S. have recently reached a 50-year peak. Given vaccination rates have remained high, the concerning increase in infections points to potential limitations with the existing intramuscular pertussis vaccines,” said Dr. Ali Fattom, Senior Vice President of Vaccine Research and Development, NanoBio. “We recently tested an intranasal NE pertussis vaccine in animals and the data indicates important benefit in comparison to current intramuscular vaccines. NanoBio’s vaccine elicited robust systemic immunity and triggered a mucosal immune response believed to be critical in reducing the time pertussis is carried in the respiratory tract of individuals exposed to the bacteria. A reduction of carriage would lead directly to lower rates of transmission.”

Link to full press release